SCHEMBL4028355

SCHEMBL4028355

CC(C)(Oc1cccc([C@@H]2CCCN(C(=O)OCc3ccc(C4CC4)cc3)C2)c1)C(=O)O

nearest known ligand 0.86

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BCL9 O00512 19/20 0.86
CTNNB1 P35222 19/20 0.86
PPARA Q07869 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4033670 1.00 BCL9 (0.86) BCL9CTNNB1PPARA
SCHEMBL4028360 1.00 BCL9 (0.86) BCL9CTNNB1PPARA
SCHEMBL4030115 0.97 BCL9 (0.85) BCL9CTNNB1PPARA
SCHEMBL4030111 0.97 BCL9 (0.85) BCL9CTNNB1PPARA
SCHEMBL4030427 0.94 BCL9 (0.88) BCL9CTNNB1PPARA
SCHEMBL4030421 0.94 BCL9 (0.88) BCL9CTNNB1PPARA
SCHEMBL4029177 0.93 BCL9 (0.86) BCL9CTNNB1PPARA
SCHEMBL4029170 0.93 BCL9 (0.86) BCL9CTNNB1PPARA
SCHEMBL4029660 0.92 BCL9 (0.85) BCL9CTNNB1PPARA
SCHEMBL4029666 0.92 BCL9 (0.85) BCL9CTNNB1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567493-B1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PROD INC (US) 2009-03-18 EP claimed
US-20070281935-A1 Use PFIZER INC. (US) 2007-12-06 US claimed
US-20070191429-A1 PPAR ACTIVATORS PFIZER INC. (US) 2007-08-16 US claimed
US-7199243-B2 Piperidine compounds useful as PPAR activators PFIZER INC. (US) 2007-04-03 US claimed
EP-1753426-A2 RUMINANT TREATMENTS Pfizer Products Incorporated (US) 2007-02-21 EP claimed
WO-2005115389-A2 SPECIFIC PPAR AGONISTS FOR TREATING NEGATIVE ENERGY BALANCE PFIZER PRODUCTS INC. (US) 2005-12-08 WO claimed
EP-1567493-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS Pfizer Products Inc. (US) 2005-08-31 EP claimed
US-20040157885-A1 PPAR activators PFIZER INC 2004-08-12 US claimed
WO-2004048334-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PRODUCTS INC. (US) 2004-06-10 WO claimed
EP-1567493-B1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PROD INC (US) 2009-03-18 EP disclosed
US-20070191429-A1 PPAR ACTIVATORS PFIZER INC. (US) 2007-08-16 US disclosed
US-7199243-B2 Piperidine compounds useful as PPAR activators PFIZER INC. (US) 2007-04-03 US disclosed
EP-1567493-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS Pfizer Products Inc. (US) 2005-08-31 EP disclosed
US-20040157885-A1 PPAR activators PFIZER INC 2004-08-12 US disclosed
WO-2004048334-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PRODUCTS INC. (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191429-A1 PPAR ACTIVATORS PPARA, PPARG, PPARD BCL9 2684/4885CTNNB1 2280/4885PPARA 1/4885
US-20040157885-A1 PPAR activators PPARA, PPARG, PPARD BCL9 2684/4885CTNNB1 2280/4885PPARA 1/4885
US-20070281935-A1 Use ALPP, CPT1A, PIGS BCL9 3385/4885CTNNB1 995/4885PPARA 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.